Clinical Trial: Prolensa (Bromfenac) 0.07% QD vs. Ilevro (Nepafenac) 0.3% QD for Treatment of Ocular Inflammation Post Cataract Surgery
Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional
Official Title: Clinical Outcomes of Prolensa (Bromfenac Ophthalmic Solution) 0.07% QD vs. Ilevro (Nepafenac Ophthalmic Suspension) 0.3% QD for Treatment of Ocular Inflammation Associated With Cataract Surgery
Brief Summary: To investigate inflammation, visual acuity and macular thickness after treatment with Prolensa vs Ilevro after cataract surgery.
Detailed Summary: To investigate the clinical outcomes for inflammation, visual acuity and macular thickness after treatment with Prolensa (bromfenac ophthalmic solution) 0.07% QD in subjects who have undergone cataract extraction with posterior chamber intraocular lens implantation.
Sponsor: Melissa Toyos, MD
Current Primary Outcome: Treatment of inflammation associated with cataract surgery [ Time Frame: 42 days +/-7 days ]
Original Primary Outcome: Treatment of inflammation associated with cataract surgery [ Time Frame: Up to tweny-six days ]
Current Secondary Outcome: Visual Acuity [ Time Frame: 42 days +/-7 days ]
Original Secondary Outcome: Visual Acuity [ Time Frame: End of Study ]
Information By: Discover Vision Centers
Dates:
Date Received: April 16, 2013
Date Started: April 2013
Date Completion: December 2015
Last Updated: June 10, 2015
Last Verified: June 2015